SpectraSan24 Developed for Institutional and Commercial Markets; Cruise Control Targeted to Cruise Lines
SAN DIEGO, Feb. 12 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE), a leader in nontoxic solutions for global health challenges, today announced an agreement with BioTech Medical LLC for distribution of PURE's silver dihydrogen citrate SDC-based disinfectant under the name SpectraSan24(TM). The agreement also grants BioTech Medical rights to market PURE's Cruise Control(R) product to the cruise line industry.
Andrea L. Goren, Executive Director of BioTech Medical LLC, stated, "We are significantly expanding our Specialty Chemical Group to capitalize on the opportunity to introduce these leading-edge disinfectants to several diverse markets. We have established a dedicated marketing program to promote SpectraSan24, its competitive benefits and the impact it will have on health outcomes in a variety of settings. Our marketing efforts focus on military and government agencies, school systems, the restoration and remediation industry and, of course, healthcare providers and institutions. We also intend to market SpectraSan24 through our international channels to similar markets worldwide.
"Existing business relationships with key industry leaders allowed us to quickly commence an on-board trial of Cruise Control with a large cruise line. Although the evaluation process can be lengthy, we expect that the product could be adopted into routine use before the start of the summer holiday season," Ms. Goren added.
Ms. Goren concluded, "BioTech Medical is committed to delivering innovative and environmentally responsible technologies to address significant public health threats. We are thrilled to be able to integrate SpectraSan24 into our business to benefit the global community."
Michael L. Krall, President and CEO of PURE Bioscience, commented, "BioTech Medical has a long and lucrative track record of marketing healthcare products, especially disruptive technologies like SDC. Selling innovative products requires an investment in industry and customer education that then serves as a catalyst to drive the necessary understanding and adoption of a new technology. BioTech Medical's marketing team deploys a structured program to introduce and sell pioneering products, and we believe their strategy will result in near-term market penetration of SpectraSan24 in a variety of industries."
Krall continued, "We are also enthusiastic about BioTech Medical's rapid progress with Cruise Control; a product we continue to believe is particularly well suited to eliminate the threat of dangerous pathogens, including Norovirus, that have become serious problems for many cruise lines and other segments of the transportation and hospitality industries."
SpectraSan24, currently undergoing registration in all 50 states, carries a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a 2-minute kill time on some resistant strains of bacteria, 10-minute kill time on fungi, 30-second kill time on HIV Type I, and 10-minute kill time on other pathogenic viruses. These claims distinguish the efficacy of SpectraSan24 from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, SpectraSan24 is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products.
Cruise Control: 24-Hour Protection Against Norovirus
Based on PURE's patented silver dihydrogen citrate (SDC) molecule, Cruise Control provides the first 24-hour residual protection against Norovirus. This highly concentrated product is designed to be mixed with water at the point of use to create a non-toxic hard surface antimicrobial. Cruise Control is being marketed to the cruise ship industry to help combat outbreaks of Norovirus, or "stomach flu." According to PURE, no EPA registered products have carried a residual kill claim for a virus, and, consequently, no EPA protocol exists to evaluate products for such a claim. Therefore, Cruise Control is first being marketed internationally to the cruise ship industry and is not currently available for sale in the United States.
About BioTech Medical, LLC
BioTech Medical LLC is a North Canton, Ohio based division of privately-held Suarez Corporation Industries (SCI), a leading international marketing company. SCI distributes hundreds of diversified products around the world and has established its success through product innovation and multi-channel marketing. BioTech Medical's multiple business segments are each focused on the distribution of innovative healthcare products.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
BioTech Medical LLC Contact: PURE Investor Contact: Andrea Goren Paul G. Henning, Vice President (800) 284-9857 Cameron Associates firstname.lastname@example.org (212) 554-5462 email@example.com PURE Media Contact: Suzanne Matick Gutenberg Communications (408) 335-6964 Suzanne@gutenbergpr.com
|SOURCE PURE Bioscience|
Copyright©2009 PR Newswire.
All rights reserved